Caricamento...
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
In patients with portopulmonary hypertension (n = 13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC imp...
Salvato in:
| Pubblicato in: | Pulm Circ |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5987907/ https://ncbi.nlm.nih.gov/pubmed/29565224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2045894018769305 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|